GR3035542T3 - Use of nicotinic analogs for treatment of degenerative diseases of the nervous system. - Google Patents

Use of nicotinic analogs for treatment of degenerative diseases of the nervous system.

Info

Publication number
GR3035542T3
GR3035542T3 GR20010400383T GR20010400383T GR3035542T3 GR 3035542 T3 GR3035542 T3 GR 3035542T3 GR 20010400383 T GR20010400383 T GR 20010400383T GR 20010400383 T GR20010400383 T GR 20010400383T GR 3035542 T3 GR3035542 T3 GR 3035542T3
Authority
GR
Greece
Prior art keywords
treatment
nervous system
pct
degenerative diseases
anabaseine
Prior art date
Application number
GR20010400383T
Other languages
English (en)
Inventor
John A Zoltewicz
William R Kem
Edwin M Meyer
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of GR3035542T3 publication Critical patent/GR3035542T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GR20010400383T 1991-03-01 2001-03-09 Use of nicotinic analogs for treatment of degenerative diseases of the nervous system. GR3035542T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66286791A 1991-03-01 1991-03-01
PCT/US1992/001451 WO1992015306A1 (en) 1991-03-01 1992-02-27 Use of nicotinic analogs for treatment of degenerative diseases of the nervous system

Publications (1)

Publication Number Publication Date
GR3035542T3 true GR3035542T3 (en) 2001-06-29

Family

ID=24659568

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20010400383T GR3035542T3 (en) 1991-03-01 2001-03-09 Use of nicotinic analogs for treatment of degenerative diseases of the nervous system.

Country Status (12)

Country Link
US (4) US5516785A (el)
EP (1) EP0573568B1 (el)
JP (1) JP2657583B2 (el)
KR (2) KR0137003B1 (el)
AT (1) ATE198830T1 (el)
AU (1) AU652434B2 (el)
CA (2) CA2362719A1 (el)
DE (1) DE69231658T2 (el)
DK (1) DK0573568T3 (el)
ES (1) ES2153357T3 (el)
GR (1) GR3035542T3 (el)
WO (1) WO1992015306A1 (el)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2153357T3 (es) * 1991-03-01 2001-03-01 Univ Florida Uso de analogos nicotinicos para el tratamiento de enfermedades degenerativas del sistema nervioso.
US5276043A (en) * 1992-04-10 1994-01-04 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5977144A (en) * 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
CA2142610C (en) * 1992-08-31 2003-09-16 William R. Kem Anabaseine derivatives useful in the treatment of degenerative diseases of the nervous system
US5510355A (en) * 1994-09-06 1996-04-23 Bencherif; Merouane Depolarizing skeletal muscle relaxants
JP3219946B2 (ja) * 1994-09-22 2001-10-15 大鵬薬品工業株式会社 新規製造中間体及びピリジン誘導体の製造方法
US5703100A (en) * 1994-11-10 1997-12-30 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5723477A (en) * 1994-11-10 1998-03-03 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5594011A (en) * 1994-11-10 1997-01-14 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5705512A (en) * 1994-11-10 1998-01-06 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5677459A (en) * 1994-11-10 1997-10-14 Sibia Neurosciences, Inc. Methods for the preparation of modulators of acetylcholine receptors
US6194581B1 (en) 1995-04-07 2001-02-27 Merck & Co., Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5794887A (en) 1995-11-17 1998-08-18 Komerath; Narayanan M. Stagnation point vortex controller
ZA984638B (en) 1997-05-30 1998-12-11 Neurosearch As Azacyclooctane and heptane derivatives their preparation and use
US6350479B1 (en) 1998-06-05 2002-02-26 Regent Court Technologies Treating depression with alcohol extracts of tobacco
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
US6750234B2 (en) * 2001-03-08 2004-06-15 University Of Kentucky Research Foundation Methods for increasing leptin levels using nicotinic acid compounds
US7091357B2 (en) 2001-12-26 2006-08-15 University Of Kentucky Research Foundation Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
US20030162770A1 (en) 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US7160551B2 (en) * 2002-07-09 2007-01-09 The Board Of Trustees Of The University Of Illinois Injectable system for controlled drug delivery
EP1531820A1 (en) * 2002-08-30 2005-05-25 Memory Pharmaceuticals Corporation Anabaseine derivatives useful in the treatment of neurodegenerative diseases
RU2391341C2 (ru) 2002-09-25 2010-06-10 Мемори Фармасьютиклз Корпорейшн Индазолы, бензотиазолы, бензоизотиазолы, их получение и применение
US7736636B2 (en) * 2003-02-12 2010-06-15 Shaker Mousa Method for treating occlusive vascular diseases & wound healing
CA2463719A1 (en) * 2003-04-05 2004-10-05 F. Hoffmann-La Roche Ag Nucleotide analogs with six membered rings
US7816356B2 (en) 2003-11-14 2010-10-19 Daniel Yohannes Aryl and heteroaryltetrahydrocyclobutapyrroles as nicotinic acetylcholine receptor ligands
NZ550534A (en) 2004-03-25 2009-07-31 Memory Pharm Corp Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
US20050288333A1 (en) * 2004-06-08 2005-12-29 Kem William R Controlling angiogenesis with anabaseine analogs
KR20060038010A (ko) * 2004-10-29 2006-05-03 재단법인서울대학교산학협력재단 니코틴산을 포함하는, 갭 결합을 통한 세포간 정보전달의억제 및 항상성의 불균형과 관련된 질환의 예방 또는치료용 조성물
US7930222B2 (en) * 2006-06-27 2011-04-19 Quiq, Inc. Method and system for preparing a set of paired identification labels
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
JP2011516489A (ja) * 2008-03-31 2011-05-26 ユニバーシティ・オブ・サウス・フロリダ 疾患誘発性運動失調症および非運動失調性平衡異常の治療法
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
WO2011022467A2 (en) * 2009-08-21 2011-02-24 University Of Florida Research Foundation, Inc. Controlled-release formulations of anabaseine compounds and uses thereof
AR082138A1 (es) * 2010-07-12 2012-11-14 Hoffmann La Roche 1-hidroxiimino-3-fenil-propanos
US9440948B2 (en) 2010-09-03 2016-09-13 University Of Florida Research Foundation, Inc. Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use
CA2834280C (en) * 2011-04-28 2023-01-10 Rock Creek Pharmaceuticals, Inc. Methods of administering anatabine to treat autism spectrum disorders and seizure disorders
CN104169269A (zh) 2011-08-29 2014-11-26 Rcp发展股份有限公司 用于抗炎支持的产品
US10340082B2 (en) 2015-05-12 2019-07-02 Capacitor Sciences Incorporated Capacitor and method of production thereof
US10347423B2 (en) 2014-05-12 2019-07-09 Capacitor Sciences Incorporated Solid multilayer structure as semiproduct for meta-capacitor
WO2015175558A2 (en) 2014-05-12 2015-11-19 Capacitor Sciences Incorporated Energy storage device and method of production thereof
RU2017112074A (ru) 2014-11-04 2018-12-05 Кэпэситор Сайенсиз Инкорпорейтед Устройства для хранения энергии и способы их получения
WO2016138310A1 (en) 2015-02-26 2016-09-01 Capacitor Sciences Incorporated Self-healing capacitor and methods of production thereof
US9932358B2 (en) 2015-05-21 2018-04-03 Capacitor Science Incorporated Energy storage molecular material, crystal dielectric layer and capacitor
US9941051B2 (en) 2015-06-26 2018-04-10 Capactor Sciences Incorporated Coiled capacitor
US10026553B2 (en) * 2015-10-21 2018-07-17 Capacitor Sciences Incorporated Organic compound, crystal dielectric layer and capacitor
US10305295B2 (en) 2016-02-12 2019-05-28 Capacitor Sciences Incorporated Energy storage cell, capacitive energy storage module, and capacitive energy storage system
US10153087B2 (en) 2016-04-04 2018-12-11 Capacitor Sciences Incorporated Electro-polarizable compound and capacitor
US9978517B2 (en) 2016-04-04 2018-05-22 Capacitor Sciences Incorporated Electro-polarizable compound and capacitor
US11096932B2 (en) 2016-09-29 2021-08-24 The Uab Research Foundation Methods and compositions for increasing mucus clearance
US10395841B2 (en) 2016-12-02 2019-08-27 Capacitor Sciences Incorporated Multilayered electrode and film energy storage device
WO2021028005A1 (en) * 2019-08-15 2021-02-18 Elkazaz Mohamed Fadly Abd El Ghany A medicament comprising anabasine for treatment of asthma, chest allergy and atopic dermatits

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3247213A (en) * 1961-04-12 1966-04-19 Shell Oil Co Heterocyclic nitrogen compounds
SU530684A1 (ru) * 1971-10-27 1976-10-05 Ташкентский Ордена Трудового Красного Знамени Государственный Университет Им.В.И.Ленина Средство дл лечени хронического никотинизма
US4155909A (en) * 1977-06-13 1979-05-22 Philip Morris Incorporated 2-Alkyl nicotinoids and processes for their production
US4183931A (en) * 1977-09-08 1980-01-15 Research Corporation 2-Ketoalkyl-4(3H)-quinazolinones
US4360531A (en) * 1981-04-09 1982-11-23 The Upjohn Company Substituted cycloalkanes
US4680172A (en) * 1985-03-05 1987-07-14 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4965074A (en) * 1985-03-05 1990-10-23 Ciba-Geigy Corporation Method of treating memory impairment
IE62662B1 (en) * 1989-01-06 1995-02-22 Elan Corp Plc Use of nicotine in the treatment of conditions susceptible to said treatment
US5109017A (en) * 1990-09-26 1992-04-28 Fisons Corporation (2-thienyl)alkylamine derivatives having neuroprotective properties
ES2153357T3 (es) * 1991-03-01 2001-03-01 Univ Florida Uso de analogos nicotinicos para el tratamiento de enfermedades degenerativas del sistema nervioso.
US5276043A (en) 1992-04-10 1994-01-04 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function

Also Published As

Publication number Publication date
JPH06509322A (ja) 1994-10-20
WO1992015306A1 (en) 1992-09-17
DE69231658T2 (de) 2001-09-06
AU1455692A (en) 1992-10-06
DK0573568T3 (da) 2001-04-23
KR0175638B1 (ko) 1999-02-18
ES2153357T3 (es) 2001-03-01
CA2362719A1 (en) 1992-09-17
US5602257A (en) 1997-02-11
CA2105071A1 (en) 1992-09-02
EP0573568B1 (en) 2001-01-24
ATE198830T1 (de) 2001-02-15
CA2105071C (en) 2002-05-14
EP0573568A1 (en) 1993-12-15
US6630491B1 (en) 2003-10-07
KR0137003B1 (ko) 1998-04-25
EP0573568A4 (en) 1994-09-21
AU652434B2 (en) 1994-08-25
DE69231658D1 (de) 2001-03-01
US5840906A (en) 1998-11-24
JP2657583B2 (ja) 1997-09-24
US5516785A (en) 1996-05-14

Similar Documents

Publication Publication Date Title
GR3035542T3 (en) Use of nicotinic analogs for treatment of degenerative diseases of the nervous system.
LTIP919A (en) Drugs and process for preparing thereof
NL300787I1 (el)
DE69230040D1 (de) Biokompatibles implantat für die zeitliche abstimmung der ovulation von stuten
GR3036548T3 (en) Apparatus and method for preparing solid forms with controlled release of the active ingredient
EP0659078A4 (en) ANABASEIN DERIVATIVES FOR TREATING DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM.
HRP940386B1 (en) New pharmaceutical formulation
BG103179A (en) Substituted pyridines as selective cyclooxygenase-2 inhibitors
NO2012003I2 (no) 4-aminopyridin
PL275056A1 (en) Method of obtaining derivatives of 4-aminopyridine
SU1769868A1 (ru) Cпocoб лeчehия пocлeдctbий poдoboй tpabmы плeчeboгo cплetehия
TW261532B (el)
ES2006619A6 (es) Un metodo para preparar derivados de piridil-y pirimidil-piperazinas.
HU9403299D0 (en) Melatonin for use in treating desynchronisation disorders
GR3019866T3 (en) Medicament for treating hyperlipidaemia and/or atherosclerosis
MX9202015A (es) Esteres aril alquilicos de acido 4,5-di hidroxi -9,10- di hidro-9,10-di oxo --2- antracen carboxilico que tienen actividad terapeutica.
PL318262A1 (en) Imidazopyridine azolydinones
WO1989005644A3 (fr) Thienotricyclene
GB9500024D0 (en) Treatment of excessive cell proliferation disorders
ZA936018B (en) Method for inhibiting HIV replication using IL-4
GR3022935T3 (en) Product and use of it for the treatment of catabolic states comprising authentic igf-1 and hypocaloric amount of nutritients
AU5417696A (en) Substituted tetronic acids useful for treating hiv and other retroviruses
AU1884895A (en) Use of phosphorus derivatives of alkaloids for treating endocrinopathies
GR3027682T3 (en) 4-guanidinobutyramide for improving blood circulation.
ZA983211B (en) Use of mizolastine for preparing medication for the treatment of inflammation